Jerby-Arnon, Livnat http://orcid.org/0000-0002-4037-386X
Neftel, Cyril
Shore, Marni E.
Weisman, Hannah R.
Mathewson, Nathan D. http://orcid.org/0000-0002-8895-2609
McBride, Matthew J.
Haas, Brian
Izar, Benjamin http://orcid.org/0000-0003-2379-6702
Volorio, Angela
Boulay, Gaylor
Cironi, Luisa
Richman, Alyssa R.
Broye, Liliane C.
Gurski, Joseph M. http://orcid.org/0000-0002-1668-3542
Luo, Christina C.
Mylvaganam, Ravindra
Nguyen, Lan
Mei, Shaolin
Melms, Johannes C.
Georgescu, Christophe
Cohen, Ofir
Buendia-Buendia, Jorge E.
Segerstolpe, Asa
Sud, Malika
Cuoco, Michael S. http://orcid.org/0000-0003-2163-5120
Labes, Danny
Gritsch, Simon
Zollinger, Daniel R.
Ortogero, Nicole
Beechem, Joseph M.
Petur Nielsen, G.
Chebib, Ivan
Nguyen-Ngoc, Tu
Montemurro, Michael
Cote, Gregory M.
Choy, Edwin http://orcid.org/0000-0001-9896-8084
Letovanec, Igor
Cherix, Stéphane http://orcid.org/0000-0001-5500-0508
Wagle, Nikhil
Sorger, Peter K. http://orcid.org/0000-0002-3364-1838
Haynes, Alex B.
Mullen, John T.
Stamenkovic, Ivan
Rivera, Miguel N.
Kadoch, Cigall http://orcid.org/0000-0002-4058-5985
Wucherpfennig, Kai W.
Rozenblatt-Rosen, Orit http://orcid.org/0000-0001-6313-3570
Suvà, Mario L. http://orcid.org/0000-0001-9898-5351
Riggi, Nicolò http://orcid.org/0000-0001-9160-1984
Regev, Aviv http://orcid.org/0000-0003-3293-3158
Article History
Received: 5 October 2019
Accepted: 14 December 2020
First Online: 25 January 2021
Competing interests
: A.R. is a founder of and equity holder in Celsius Therapeutics, an equity holder in Immunitas Therapeutics, and was a scientific advisory board member for Thermo Fisher Scientific, Syros Pharmaceuticals and Neogene Therapeutics until 1 August 2020. From 1 August 2020, A.R. is an employee of Genentech. M.L.S. is an equity holder, scientific cofounder and advisory board member of Immunitas Therapeutics. K.W.W. serves on the scientific advisory board of TCR2 Therapeutics, T-Scan Therapeutics, SQZ Biotech, Nextechinvest and receives sponsored research funding from Novartis. He is a cofounder of Immunitas Therapeutics. L.J.A, N.R., M.L.S. and A.R. are coinventors on US patent application filed by the Broad Institute relating to synovial sarcoma. O.R.-R. is an employee of Genentech and a coinventor on patent applications filed by the Broad Institute for inventions relating to single cell genomics, such as in PCT/US2018/060860 and US provisional application no. 62/745,259. D.R.Z., N.O. and J.M.B. are employees of Nanostring which developed GeoMx. C.K. is the scientific founder, fiduciary board of directors member, scientific advisory board member, shareholder and consultant for foghorn therapeutics. E.C. reports support paid to his institution for the conduct of clinical trials from Amgen, Astra Zeneca, Novartis, Bayer, Merck, Exelixis, GSK, Adaptimmune and Iterion. G.M.C. reports advisory board fees and support paid to his institution for the conduct of clinical trials from Agios, Epizyme, PharmaMar, Eisai; support paid to his institution for the conduct of clinical trials from Macrogenics, Boston Biomedical, Plexxicon, Merck KGaA / EMD Serono Research and Development Institute, CBA, SpringWorks Therapeutics, Bavarian-Nordic; compound for preclinical research and support paid to his institution for the conduct of clinical trials from Bayer. P.K.S. is a member of the SAB or Board of Directors of Applied Biomath, Glencoe Software and RareCyte and has equity in these companies. In the last five years the Sorger lab has received research funding from Novartis and Merck. The authors declare that these activities are not related to the research reported in this publication and have not influenced the conclusions in this manuscript. B.I. is a consultant for Merck and Volastra Therapeutics. N.W. is an equity holder and scientific advisory board member of Relay Therapeutics, a paid advisor to Eli Lilly and Co, and receives grant support from Puma Biotechnology. N.D.M. serves as a scientific advisor to Immunitas Therapeutics. C.N., M.E.S., H.R.W, M.J.M, B.H., B.I, A.V, G.B., L.C., A.R.Ri, L.C.B., J.M.G., C.C.L, R.M., L.N., S.M., J.C.M., C.G., O.C., J.E.B.-B., A.S., M.S., M.S.C, D.L., S.G., G. P.N., I.C., T.N.-N, M.M., E.C., I.L., S.C., A.B.H., J.T.M., I.S. and M.N.R declare no competing interests.